Immunocore to present at upcoming investor conferences
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunocore (NASDAQ: IMCR), a commercial-stage biotechnology company, has announced its participation in four major investor conferences in September 2025. The company will participate in the Cantor Global Healthcare Conference (Sept 5), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Morgan Stanley Global Healthcare Conference (Sept 10).
Immunocore specializes in developing novel TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune, and infectious diseases. Their flagship product, KIMMTRAK, is approved in multiple regions for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Details
News Market Reaction – IMCR
On Sep 4, the day this news came out, IMCR closed 0.03% below the previous close.
Data tracked by StockTitan Argus for the Sep 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Immunocore to present at upcoming investor conferences
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.
Cantor Global Healthcare Conference
Fireside Chat: Friday, September 5, 2025, at 8:35 a.m. EDT
H.C. Wainwright 27th Annual Global Investment Conference
1x1 and small group meetings: Monday, September 8, 2025
Baird 2025 Global Healthcare Conference
Fireside Chat: Tuesday, September 9, 2025, at 10:15 a.m. EDT
Morgan Stanley 23rd Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 10, 2025, at 1:50 p.m. EDT
Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow Immunocore on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.